## FASN-IN-4 tosylate

Cat. No.:	HY-12648A	$\bigtriangledown$
CAS No.:	2095432-57-6	O <sub>S</sub> N_
Molecular Formula:	$C_{33}H_{35}N_{3}O_{7}S_{2}$	
Molecular Weight:	649.78	N S
Target:	Fatty Acid Synthase (FASN); SARS-CoV	
Pathway:	Metabolic Enzyme/Protease; Anti-infection	<sup>Q</sup> ∖ <sub>2</sub> ∠OH
Storage:	<b>4°C, sealed storage, away from moisture</b> * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	, o l

### SOLVENT & SOLUBILITY

In Vitro	DMSO : 12.5 mg/mL (19.24 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.5390 mL	7.6949 mL	15.3898 mL		
		5 mM	0.3078 mL	1.5390 mL	3.0780 mL		
		10 mM	0.1539 mL	0.7695 mL	1.5390 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (1.92 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (1.92 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.25 mg/mL (1.92 mM); Clear solution						

Diological Activity				
Description	FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC <sub>50</sub> of 10 nM (WO2012064642A1, compound 29) <sup>[1]</sup> . FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC <sub>50</sub> of 18.6 nM <sup>[2]</sup> .			
IC <sub>50</sub> & Target	IC50: 10 nM (FASN) <sup>[1]</sup> EC50: 18.6 nM (SARS-CoV-2) <sup>[2]</sup>			
In Vitro	The FASN inhibitor, FASN-IN-4 tosylate inhibits SARS-CoV-2 replication, and has the potential for COVID-19 research <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

# Product Data Sheet



### CUSTOMER VALIDATION

- Nat Metab. 2021 Sep 27;1-10.
- Cell Biosci. 2022 Sep 16;12(1):158.
- Sci China Life Sci. 2021 May 27;1-21.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Nicholas D. Adams, et al. Fatty acid synthase inhibitors. WO2012064642A1.

[2]. Junjun Chu, et al. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat Metab. 2021 Nov;3(11):1466-1475.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA